Dr. Carlos Luis Jiménez Klingberg (Hagen/ DE), Dr. Katja Konietzko (Hagen/ DE), Dr. Lutz Pichl (Hagen/ DE), Regine Rietz (Hagen/ DE), Dr. Thomas Zeiler (Hagen/ DE)
Background
Potential donors who have a malaria risk are currently examined by means of NAT before collecting a first donation in the DRK BSD West. According to a recommendation of the WGB, it is preferable to be tested with an infectious serological test. In 2022 we identified two potential donors who had plasmodia genome in the NAT. Only one case showed a positive result in an infection serological test for antibodies against plasmodia.
Methods
In accordance with GL, nucleic acid testing (NAT) by PCR is performed at our facility after a retention period of 4 years using the AltoStar Purification Kit 1.5 combined with RealStar Malaria PCR Kit 1.0 and Alto Star AM 16 system (altona Diagnostics). In addition to the validated molecular biological testing, an infectious serological examination by means of an ELISA, which is approved for donor testing in Germany, shall be introduced. Therefore, the NovaLISA malaria immunoassay and the ETI-Max 3000 analyser will be used. The results of the two methods will be compared.
Results
Still pending.
Conclusion
The results are to be discussed against the background of the WBG recommendation. The question will be raised whether PCR tests are dispensable or whether the combination of infection serological and NAT tests should be preferred.
Offenlegung Interessenkonflikt:
Keine Interessenskonflikte